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NEW IN 2017, UPDATE OF POLISH FORUM FOR 
PREVENTION GUIDELINES ON HYPERTENSION
1. New data on epidemiology of hypertension in the Polish 
population
2. New system of cardiovascular risk assessment for the 
population of Poland
3. New treatment blood pressure (BP) goals
4. Modified recommendations on non-pharmacological 
treatment
5. Modified recommendations on combination treatment, 
including new recommended combinations
1. DEFINITION (DIAGNOSIS) OF HYPERTENSION
Hypertension is defined as high BP (systolic [SBP] ≥ 140 mm Hg 
and/or diastolic [DBP] ≥ 90 mm Hg) during two separate 
visits or during only one office visit if reliable information 
on high BP in the medical records, in the patient his-
tory, or from home measurements is available. It is also 
allowable to diagnose hypertension based on BP meas-
urement during only one office visit if SBP ≥ 180 mm Hg 
and/or DBP ≥ 110 mm Hg after exclusion of factors that 
might increase BP acutely (such as pain or fear). BP should 
be measured at least twice during each office visit. The clas-
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sification of hypertension is presented in Table 1 whereas 
definitions of hypertension by office and out-of-office BP 
levels are presented in Table 2 [1–4].
2. BLOOD PRESSURE MEASUREMENT
The reliability of BP measurements depends on proper 
measurement using a certified device with its accuracy being 
checked periodically (e.g. every six months). Wrist devices are 
not recommended nowadays; however, their use can be justi-
fied in obese patients with very large arm circumference [2–4]. 
At the first visit BP should be measured on both arms; 
subsequently the arm with higher BP value should be always 
chosen [2–4]. The size of bladder should depend on the 
arm circumference. The cuff should be placed at heart level 
regardless of the position of the patient. The patient should 
sit for 3–5 min before beginning the BP measurements. BP 
should be measured at least twice with the patient in the sit-
ting position, the measurements should be spaced 1–2 min 
apart, and additional measurement is required if the first two 
differ by more than 10 mm Hg [2–4]. 
3. PREVALENCE OF HYPERTENSION
Hypertension is a social problem in Poland because its 
prevalence is about 33% in the adult Polish population (over 
10.5 million cases, including almost one million persons 
aged > 80 years). Almost 30% of hypertensives in Poland are 
not aware of their disease. The control rate of hypertension 
is only 26%. 
4. ETIOPATHOGENESIS OF HYPERTENSION 
The etiopathogenesis of hypertension is complex in most cases; 
therefore, the identification of the causal factor is often not 
possible. In all cases, particularly in young patients or those 
with severe hypertension, efforts should be made to identify 
secondary hypertension. This may lead to permanent recovery.
5. CARDIOVASCULAR RISK ASSESSMENT  
AND LABORATORY INVESTIGATIONS
The cardiovascular risk assessment should be based on the 
Pol-SCORE 2015 system, but risk factors not included in the 
Pol-SCORE 2015 charts (e.g. overweight, family history, diabe-
tes) should also be taken into account [5]. The cardiovascular 
risk increases with increasing BP continuously, beginning from 
values considered as normal. 
The routine laboratory investigation panel includes: 
electrocardiogram, blood cell count, fasting glucose, total 
cholesterol, low-density lipoprotein cholesterol, high-density 
lipoprotein cholesterol, triglycerides, potassium, sodium, uric 
acid, creatinine (with glomerular filtration rate calculation), and 
urine analysis including a test for albuminuria [3, 4]. In addi-
tion, the detailed history, physical examination, or results of the 
routine panel test may suggest other tests aimed at diagnosis of 
secondary hypertension, organ damage, or coexisting disease.
6. GOALS OF THERAPY
The primary goal is to reduce the risk of death and cardio-
vascular events as well as to reduce the risk of heart failure, 
Table 1. Classification of office blood pressure (BP) levels [3, 4]
Category Systolic BP [mm Hg] Diastolic BP [mm Hg]
Optimal BP < 120 and < 80
Normal BP 120–129 and/or 80–84
High normal BP 130–139 and/or 85–89
Grade 1 hypertension (mild) 140–159 and/or 90–99
Grade 2 hypertension (moderate) 160–179 and/or 100–109
Grade 3 hypertension (severe) ≥ 180 and/or ≥ 110
Isolated systolic hypertension* ≥ 140 and < 90
*Isolated systolic hypertension should be graded 1, 2, or 3 according to systolic BP values in the ranges indicated.
Table 2. Definitions of hypertension by office and out-of-office blood pressure (BP) levels [3, 4].
Method of BP measurement Systolic BP [mm Hg] Diastolic BP [mm Hg]
Office BP ≥ 140 and/or ≥ 90
Ambulatory BP:
Daytime (or awake) ≥ 135 and/or ≥ 85
Nighttime (or asleep) ≥ 120 and/or ≥ 70
24-hours ≥ 130 and/or ≥ 80
Home BP ≥ 135 and/or ≥ 85
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kidney disease, and dementia development. It is essential to 
reduce BP to recommended values as well as to control all 
other modifiable cardiovascular risk factors. 
The BP goal is < 140/90 mm Hg in non-diabetic, non-el-
derly patients. The goal in diabetics is < 140/85 mm Hg [6]. 
In patients > 60 years old with initial SBP ≥ 160 mm Hg, it is 
recommended to reduce SBP to between 150 and 140 mm Hg, 
however, in fit patients < 80 years old, a target < 140 mm Hg 
may be considered if treatment is well tolerated. In some of 
these patients a target < 120 mm Hg may be considered if 
at (very) high risk [6]. In individuals > 80 years old and with 
initial SBP ≥ 160 mm Hg, it is recommended that SBP is re-
duced to between 150 and 140 mm Hg, provided they are 
in good physical and mental condition [6].
7. NON-PHARMACOLOGICAL TREATMENT
Lifestyle changes are important for both prevention and treat-
ment of hypertension. Non-pharmacological treatment should 
be implemented immediately in all patients with hypertension. 
It is recommended to [6]:
 — stop smoking;
 — normalise body weight (body mass index 20–25 kg/m2, 
waist < 102 cm in men and < 88 cm in women);
 — perform at least 150 min a week of moderate intensity 
or 75 min a week of vigorous intensity aerobic physical 
activity or an equivalent combination thereof. Sessions 
of physical activity should last at least 10 min each, and 
be spread throughout the week, i.e. on 4–5 days a week 
and preferably every day of the week;
 — reduce salt intake to < 5 g/day;
 — increase fruit intake to at least 200 g/day;
 — increase vegetables intake to at least 200 g/day;
 — limit alcohol intake to below 10 g of ethanol in women 
and below 20 g of ethanol in men.
In addition, sugar-sweetened soft drinks should be dis-
couraged. Lifestyle changes in addition to BP lowering favour-
ably influence other cardiovascular risk factors. 
8. PHARMACOLOGICAL TREATMENT
Drug treatment should always be combined with healthy 
lifestyle changes. Antihypertensive drugs should be prescribed 
immediately to patients:
 — with moderate or severe hypertension (grade 2 or 3);
 — with mild hypertension (grade 1) at high or very high 
cardiovascular risk.
In patients with mild hypertension (grade 1) and low 
or moderate cardiovascular risk, lifestyle changes should be 
implemented, and the decision about drug therapy initiation 
should be made after assessment of non-pharmacological 
treatment effect and full cardiovascular risk stratification. 
Excessive delay in initiation of pharmacotherapy is not 
beneficial. 
9. INDIVIDUALISATION OF THERAPY
Beneficial and adverse effects of drugs, metabolic disorders, 
organ damage, and co-morbidities should be taken into ac-
count when choosing antihypertensive drugs [3, 4, 6]. 
General recommendations
 — In uncomplicated hypertension it is recommended to start 
therapy with a drug belonging to one of the following 
classes: angiotensin converting enzyme inhibitors (ACEI), 
beta-blockers, calcium antagonists, diuretics, and sartans. 
Long-acting drugs are generally preferred. 
 — Monotherapy may be effective in patients with mild 
hypertension.
 — A two-drug regimen should be a preferred option when 
starting pharmacotherapy in patients with moderate or 
severe hypertension as well as in patients at high or very 
high cardiovascular risk. Fixed-dose, single-pill combina-
tions should be preferred. 
 — The lack of combination treatment is often a cause of 
uncontrolled hypertension. 
Preferred drug combinations
 — ACEI or sartan + thiazide or thiazide-like diuretic
 — ACEI or sartan + calcium antagonist
 — Calcium antagonist + thiazide or thiazide-like diuretic
 — Calcium antagonist + beta-blocker
 — ACEI + beta-blocker
The combination of a beta-blocker with a diuretic should 
be considered as possible; however, the influence of these drugs 
on lipids and glucose metabolism should be taken into account.
Co-morbidities
The co-morbidities should be taken into account when choos-
ing antihypertensive drugs. For example, the combination 
of an ACEI with a beta-blocker is preferred in patients after 
myocardial infarction, whereas a thiazide-like diuretic in 
combination with an ACEI or a sartan should be preferred in 
patients after stroke. The choice of drugs should be influenced 
by their preventive effects and clinical trial results [7]. 
10. MONITORING OF BLOOD PRESSURE
Blood pressure should be measured during every follow-up 
visit (office BP). Patients should be informed about the need 
of BP measurements at home. 
Home BP monitoring (HBPM): BP should be measured 
daily on seven consecutive days (preferentially in the week 
preceding the visit). These readings often influence the deci-
sion on antihypertensive therapy modification. 
Ambulatory BP monitoring (ABPM) is more closely related 
to cardiovascular events risk and better correlated with organ 
damage compared to office measurements. Both HBPM and 
ABPM allow for diagnosis of white-coat hypertension and 
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white-coat effect as well as masked hypertension. In addition, 
ABPM allows for detection of morning BP surge and lack of 
nocturnal BP fall (non-dipper) or extreme nocturnal BP fall 
(extreme dipper). It also allows for short-term BP variability 
assessment. 
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Serdecznie zapraszamy na doroczne spotkanie największej sekcji Polskiego Towarzystwa  
Kardiologicznego. Tradycyjnie będzie ono poświęcone najnowszym osiągnięciom technologicznym 
oraz naukowym w dziedzinie echokardiografii, a także zastosowaniom praktycznym w konkretnych 
sytuacjach klinicznych. Konferencja będzie niewątpliwie okazją do pogłębienia wiedzy zarówno dla 
doświadczonych echokardiografistów, jak i tych, którzy dopiero rozpoczynają naukę tej fascynującej 
techniki diagnostycznej. Wśród wykładowców będą autorytety, najbardziej znani polscy specjaliści 
w tej dziedzinie. Podczas wystawy towarzyszącej Konferencji zostanie zaprezentowana najnowsza 
aparatura echokardiograficzna.
Szczegółowe informacje znajdują się na stronie: www.echo2017.skolamed.pl 
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